Nafamostat mesylate monotherapy in patients with moderate COVID-19 : A single-center retrospective study

In conclusion, nafamostat mesylate monotherapy did not improve clinical outcomes in patients with moderate COVID-19. The therapeutic potential of the combination of nafamostat mesylate and other antiviral agents has not been examined in the present study, and further investigation is required. Because of high incidence of hyperkalemia, regular laboratory tests are required during the use of nafamostat mesylate.PMID:35491224 | DOI:10.7883/yoken.JJID.2021.699

Source: Japanese Journal of Infectious Diseases - May 1, 2022 Category: Infectious Diseases Authors: Tomomi Soma Kentaro Fujii Ayumi Yoshifuji Taketomo Maruki Kazuto Itoh Daisuke Taniyama Takahide Kikuchi Naoki Hasegawa Morio Nakamura Source Type: research